A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Clinical trial NCT01716806 · COMPLETED

Trial details

NCT number: NCT01716806
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hodgkin Disease Peripheral T Cell Lymphoma

Start date: 2012-10-31
Primary completion: 2023-04-07
Enrollment: 131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.